Daiichi Sankyo divests Sun Pharma stake

The Japanese pharmaceuticals giant has finally exited from its troubled foray into India by selling its entire stake in Sun Pharmaceuticals for $3.2 billion.

Japanese pharmaceuticals giant Daiichi Sankyo has raised Rs201.46 billion $3.2 billion from the sale of its entire 8.9% stake in Sun Pharmaceuticals, closing the book on its ill-fated foray into India. 

Daiichi Sankyo bought a 63.4% stake in Ranbaxy Laboratories for $4.6 billion in 2008 but was shortly afterwards hit by FDA sanctions and fines for poor product safety controls at the Indian company. 

The Japanese company finally threw in the towel last April and sold the Ranbaxy stake to Sun Pharma, India's largest pharmaceuticals company by revenue, for $3.2 billion plus an 8.9% stake in the enlarged entity. ...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222